Gene Trial Targets Common Deafness

BostonSkylark Bio dosed its first GJB2 patient.

GJB2 causes far more inherited deafness than the mutation already cured.

An earlier therapy fixed otoferlin, a rare cause, but GJB2 instead rebuilds the ear’s common gap-junction cells.

Manufacturers have priced gene therapies at $2-4 million, far beyond most health systems’ reach.

Sources: STAT